Pharming Group (OTCMKTS:PHGUF) Reaches New 52-Week High - Here's Why

Key Points

• Pharming Group's share price reached a new 52-week high of $1.19 during mid-day trading, closing at $1.16 with a trading volume of 4,000 shares.
• The company maintains a debt-to-equity ratio of 0.51, indicating a relatively low level of debt compared to its equity.
• Pharming Group specializes in developing and commercializing protein replacement therapies for rare diseases, with products like RUCONEST and Joenja available in various markets.

Pharming Group NV (OTCMKTS:PHGUF - Get Free Report)'s share price reached a new 52-week high during trading on Tuesday . The company traded as high as $1.19 and last traded at $1.16, with a volume of 4000 shares. The stock had previously closed at $1.16.

Pharming Group Trading Up 12.1%

The stock has a 50 day moving average of $1.15 and a 200 day moving average of $1.01. The company has a quick ratio of 2.00, a current ratio of 2.76 and a debt-to-equity ratio of 0.51.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.